Collectively, these results imply that IL-2 deprivation may dampen the outcomes of NK cell therapy for leukemia patients with a significant effect on NKp30 expression and function, which could be circumvented by the overexpression of a stimulatory NKp30 isoform. The gene discussed is NCR3; the disease is leukemia.